PDF《OUR MISSION:》

Diluted (RMB) 基本及摊薄 (人民币:元) 0.45 0.79 0.84 1.43 2.09 Assets condition 资产状况 Total assets 总资产 949,531 2,577,415 2,831,109 3,775,975 4,560,940 Total equity attributable to equity shareholders of the Company 本公司权益股东应占总权益 277,255 2,142,849 2,457,807 2,807,836 3,433,956 Non-controlling interests 非控股权益 N/A 不适用 N/A 不适用 N/A 不适用 252,750 244,972 Total liabilities 总负债 672,276 434,566 373,302 715,389 882,012 Net cash generated from operating activities 经营活动所得现金净额 129,878 287,394 397,206 670,751 715,392 Quick ratio 速动比率 0.6 6.1 6.3 3.1 2.0 以下为截至二零一八年十二月三十一日止年度 ( 「本 年度」 或 「报告期内」 ) 的财务摘要: 二零一八年本集团营业额为人民币2,510.48百万 元,同比二零一七年增长56.75%. 二零一八年本公司权益股东应占溢利及全面收益 总额为人民币942.54百万元,同比二零一七年增长 45.66%. 二零一八年每股基本摊薄盈利为人民币2.09元, 同比二零一七年增长46.15%. 董事会建议派发末期现金股息每股人民币0.6元,须 经股东於本公司稍后举行的股东周年大会上批准. YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. 宜昌东阳光长江药业股份有限公司

4 CORPORATE PROFILE 公司简介 YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a pharmaceutical manufacturing company that focuses on the development, manufacturing and sale of pharmaceutical products in the therapeutic areas of anti-virus, endocrine diseases and cardiovascular diseases. It'

s the domestic pharmaceutical manufacturing platform of the HEC Group. The Company entered into China'

s pharmaceutical industry through the establishment of its predecessor, Yichang Changjiang Pharmaceutical Co., Ltd., in 2001. Up to now, we have been operating for more than

18 years, and are in the leading position in the domestic pharmaceutical industry in terms of pharmaceutical sales performance and research and development capability. The Company was converted into a joint stock limited company on

11 May 2015, and was listed on the Main Board of the Hong Kong Stock Exchange on

29 December 2015, with the stock code 01558.HK. Since its establishment, the Company has always followed the motto of serving the Chinese with higher standards and has a strong industrial foundation and leading competitive edges in the manufacturing, marketing and sales of pharmaceutical products. As of

31 December 2018, the Company has manufactured, promoted and sold a total of

33 pharmaceutical products in China, with more than 2,000 professional sales staff across nationwide product distribution network. Kewei (oseltamivir phosphate), one of the Company'

s core products, is the first-line drug for clinical application of anti-influenza virus in China and its granules form is the exclusive patented product of the Company. Following the inclusion in the........